Takeda Pharmaceutical (TAK) EBIT (2017 - 2026)

Takeda Pharmaceutical's EBIT history runs 10 years deep, the most recent figure standing at -$2.7 billion for Q1 2026.

• On a quarterly basis, EBIT fell 319.32% year-over-year to -$2.7 billion in Q1 2026; TTM through Mar 2026 was -$1.2 billion, a 126.57% decrease from a year earlier, with the FY2026 full-year figure at $41.3 million, down 98.16% from the prior year.
• EBIT grew to -$2.7 billion in Q1 2026 per TAK's latest filing, from -$2.7 billion in the prior quarter.
• Across five years, EBIT topped out at $2.9 billion in Q3 2025 and bottomed at -$2.7 billion in Q4 2025.
• The 5-year median for EBIT is $1.2 billion (2022), against an average of $911.2 million.
• Across the five-year window, EBIT jumped 268.02% in 2023 and tumbled 448.93% in 2025, its largest moves.
• Year by year, EBIT stood at $1.0 billion in 2022, then sank by 42.39% to $599.4 million in 2023, then tumbled by 182.19% to -$492.7 million in 2024, then tumbled by 448.93% to -$2.7 billion in 2025, then climbed by 1.88% to -$2.7 billion in 2026.
• Per Business Quant, the three latest TAK EBIT figures stand at -$2.7 billion (Q1 2026), -$2.7 billion (Q4 2025), and $2.9 billion (Q3 2025).